DeepMed Research

AIO-Studien-gGmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 2007-01-01

Employees: 11

Market Cap: -

Website: http://www.aio-studien-ggmbh.de

Clinical Trials

Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients

Completed

Conditions: Secondary Immunodeficiencies (SID)

First Posted Date: 2019-11-21

Last Posted Date: 2022-01-10

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 1086

Registration Number: NCT04172467

Locations: 🇩🇪
Privatärztliche Praxis; Innere Medizin, Hämatologie, Internistische Onkologie, Kaiserslautern, Germany

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology

Phase 1

Completed

Conditions: Adenocarcinoma of the Lung

Interventions: Drug: nintedanib-nivolumab combination therapy

First Posted Date: 2019-08-06

Last Posted Date: 2024-02-06

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 56

Registration Number: NCT04046614

Locations: 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Nivolumab and Ipilimumab
Drug: Docetaxel

First Posted Date: 2018-08-08

Last Posted Date: 2022-11-18

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 54

Registration Number: NCT03620123

Locations: 🇩🇪
Essen University Hospital, Essen, Germany

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular
Hepatic Carcinoma
Hepatocellular Cancer

Interventions: Drug: Nivolumab
Drug: TACE

First Posted Date: 2018-06-28

Last Posted Date: 2023-07-20

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 49

Registration Number: NCT03572582

Locations: 🇩🇪
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Phase 2

Completed

Conditions: Gall Bladder Carcinoma
Cholangiocarcinoma Non-resectable
Gallbladder Carcinoma Non-Resectable
Cholangiocarcinoma

Interventions: Biological: Durvalumab
Drug: Gemcitabine
Drug: Cisplatin
Biological: Tremelimumab

First Posted Date: 2018-03-22

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 128

Registration Number: NCT03473574

Locations: 🇩🇪
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

Phase 3

Completed

Conditions: Metastatic Pancreatic Cancer
Locally Advanced Pancreatic Cancer

Interventions: Drug: Irinotecan Liposomal Injection [Onivyde]

First Posted Date: 2018-03-16

Last Posted Date: 2025-04-17

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 151

Registration Number: NCT03468335

Locations: 🇩🇪
Städtisches Klinikum Brandenburg, Brandenburg, Germany
🇩🇪
MVZ Onkologische Kooperation Harz, Goslar, Germany
🇩🇪
Ambulantes Therapiezentrum Hämatologie / Onkologie, Offenburg, Germany

and more 32 locations

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Esophageal Cancers NOS
GastroEsophageal Cancer
Oesophageal Cancer
Esophageal Cancer Metastatic
Oesophageal Cancer Nos
Oesophageal Cancer Metastatic
Gastrooesophageal Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-01-31

Last Posted Date: 2022-09-29

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 66

Registration Number: NCT03416244

Locations: 🇩🇪
Universitätsmedizin Mannheim, Heidelberg University, II. Medizinische Klinik, Mannheim, Germany

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

Phase 2

Completed

Conditions: Gastric Cancer
Esophageal Cancer
Adenocarcinoma Gastric
HER2 Positive Gastric Cancer
Metastatic Gastric Cancer
GastroEsophageal Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-01-24

Last Posted Date: 2022-05-18

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 97

Registration Number: NCT03409848

Locations: 🇩🇪
Klinikum Wolfsburg - Med. II, Wolfsburg, Germany
🇩🇪
Stauferklinikum Schwäbisch Gmünd - Innere Med., Mutlangen, Germany
🇩🇪
Klinikum rechts der Isar der TU München - Innere Med. III, München, Germany

and more 32 locations

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Lung Adenocarcinoma Metastatic
Large Cell Lung Carcinoma Metastatic
Metastatic Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: nab-Paclitaxel
Drug: Durvalumab
Drug: Vinorelbine
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2017-11-17

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 200

Registration Number: NCT03345810

Locations: 🇩🇪
Klinikum Darmstadt, Darmstadt, Germany
🇩🇪
DRK-Kliniken Berlin Mitte, Berlin-Mitte, Germany
🇩🇪
Gesundheitszentrum St. Marien GmbH, Amberg, Germany

and more 27 locations

A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy

Phase 2

Terminated

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: OFF
Drug: FOLFIRI Protocol

First Posted Date: 2017-11-06

Last Posted Date: 2022-01-11

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 67

Registration Number: NCT03331640

Locations: 🇩🇪
Praxis für Innere Medizin, Friedrichshafen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy